Market news

Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Veracyte (VCYT) is adding an adjacent product to its bladder franchise following its acquisition of

Veracyte (VCYT) said late Monday it has acquired Convergent Genomics for $150 million in upfront cas

Detailed price information for Veracyte Inc (VCYT-Q) from The Globe and Mail including charting and trades.

Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.

VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.

Detailed price information for Veracyte Inc (VCYT-Q) from The Globe and Mail including charting and trades.

Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.

Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Veracyte (VCYT) Q2 2026 shows strong revenue/EBITDA growth, cash flow, and upside from Prosigna/TrueMRD. Explore valuation, moat, and guidance.

Tipranks Press Release.

Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second quarter and first half earnings results. See our latest analysis for Veracyte. The earnings beat and higher 2026 revenue guidance have coincided with strong momentum in Veracyte’s stock. The latest share price of US$59.78 reflects a 90 day share price return of 80.66%, while the 1 year total shareholder return is 152.88%. If Veracyte’s results...

Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD recurrence-monitoring test for muscle-invasive bladder cancer. Chief Executive Officer Marc Stapley

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling oil prices, and robust corporate earnings. Growth stocks, especially in technology and […]

Veracyte: Q2 Earnings Snapshot

Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectivelyConference call and webcast today at 4:30 p.m. ET

Veracyte (VCYT) delivered earnings and revenue surprises of +25.58% and +4.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences: Canaccord Genuity 46th Annual Growth Conference – Boston, MAFireside chat on Tuesday, Aug 11th at 10:30 a.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference – New York, NYFireside chat on Tuesday, Sep 15th at 5:35 p.m. Eastern Time Live audio webcasts of the com

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.

Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

This genomic diagnostics company saw a notable insider sale, as shares have surged over 70% in the past year.